Table 6 Results of the impact of sleep disturbances on HRQoL.
From: The need for comprehensive sleep disturbances assessment and management in breast cancer care
PSQI | ISI | ESS | PSQI > 5 | ISI > 8 | ESS > 10 | ISI Categories | ESS Categories | |||
|---|---|---|---|---|---|---|---|---|---|---|
GHS | r | -0.293 | -0.232 | -0.382 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | ||
Functional scales QLQ-C30 | PF | r | -0.329 | -0.364 | -0.141 | – | – | – | – | – |
p | < 0.001* | < 0.001* | 0.027** | < 0.001* | < 0.001* | 0.024** | < 0.001* | 0.011** | ||
RF | r | -0.251 | -0.239 | -0.381 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | ||
EF | r | -0.417 | -0.450 | -0.091 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | 0.157 | < 0.001* | < 0.001* | 0.018** | < 0.001* | 0.023** | ||
CF | r | -0.233 | -0.295 | -0.375 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | ||
SF | r | -0.258 | -0.204 | -0.361 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | 0.016** | < 0.001* | 0.014** | ||
Functional scales QLQ-BR23 | BRBI | r | -0.307 | -0.394 | -0.193 | – | – | – | – | – |
p | < 0.001* | < 0.001* | 0.002** | < 0.001* | < 0.001* | 0.043** | < 0.001* | 0.008** | ||
BRSEF | r | 0.011 | -0.120 | -0.104 | – | – | – | – | – | |
p | 0.897 | 0.061 | 0.003** | 0.609 | 0.260 | 0.105 | 0.210 | 0.320 | ||
BRSEE | r | 0.074 | -0.010 | -0.028 | – | – | – | – | – | |
p | 0.245 | 0.086 | 0.661 | 0.548 | 0.937 | 0.144 | 0.230 | 0.280 | ||
BRFU | r | -0.260 | -0.201 | 0.080 | – | – | – | – | – | |
p | < 0.001* | 0.002** | 0.211 | < 0.001* | < 0.001* | 0.907 | < 0.001* | 0.425 | ||
Symptom scales QLQ-C30 | FA | r | 0.354 | 0.487 | 0.258 | – | – | – | – | – |
p | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | ||
NV | r | 0.002 | 0.045 | 0.222 | – | – | – | – | – | |
p | 0.974 | 0.449 | < 0.001* | 0.317 | 0.482 | < 0.001* | 0.106 | 0.306 | ||
PA | r | 0.341 | 0.383 | 0.135 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | 0.035** | < 0.001* | < 0.001* | 0.007** | < 0.001* | < 0.001* | ||
DY | r | 0.265 | 0.294 | 0.208 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | < 0.001* | 0.017** | < 0.001* | 0.008** | < 0.001* | 0.422 | ||
SL | r | 0.668 | 0.751 | 0.052 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | 0.418 | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | ||
AP | r | 0.177 | 0.248 | 0.161 | – | – | – | – | – | |
p | 0.005** | < 0.001* | 0.012** | 0.021** | < 0.001* | 0.016** | < 0.001* | 0.530 | ||
CO | r | 0.291 | 0.313 | 0.099 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | 0.122 | < 0.001* | < 0.001* | 0.039** | < 0.001* | 0.456 | ||
DI | r | 0.159 | 0.276 | 0.113 | – | – | – | – | – | |
p | 0.013** | < 0.001* | 0.077 | 0.010** | < 0.001* | 0.005** | < 0.001* | 0.125 | ||
FI | r | 0.326 | 0.348 | 0.111 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | 0.082 | < 0.001* | < 0.001* | 0.016** | < 0.001* | 0.009** | ||
Symptom scales QLQ-BR23 | BRST | r | 0.430 | 0.523 | 0.179 | – | – | – | – | – |
p | < 0.001* | < 0.001* | 0.005** | < 0.001* | < 0.001* | 0.032** | < 0.001* | 0.025** | ||
BRBS | r | 0.300 | 0.280 | 0.174 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | 0.006** | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | ||
BRAS | r | 0.260 | 0.344 | 0.246 | – | – | – | – | – | |
p | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | < 0.001* | ||
BRHL | r | 0.171 | 0.237 | 0.135 | – | – | – | – | – | |
p | 0.007** | < 0.001* | 0.035** | 0.039** | 0.002** | 0.006** | < 0.001* | 0.012** |